HIGHLIGHTS
- who: Shaheer Khan and collaborators from the University of Pittsburgh, Pennsylvania, United States have published the Article: Intermittent MEK inhibition for the treatment of metastatic uveal melanoma, in the Journal: (JOURNAL)
- what: The aim was to estimate the maximum tolerated dose (MTD) and assess safety and tolerability. Pharmacodynamic assessments performed on serial biopsies obtained from a limited subset of patients (n=9) as part of this study demonstrated a decrease in markers corresponding with MEK inhibition at the initial on-treatment timepoint in all patients; however, 7 of the 9 patients who had reduction in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.